

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 335 423 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 09.08.95 (51) Int. Cl.⁶: **C07K 1/107, C07K 14/535, C07D 251/26**
- (21) Application number: 89105728.3
- (22) Date of filing: 31.03.89

Registered
6-CSF

(54) Modified human G-CSF.

- (30) Priority: 31.03.88 JP 80088/88
- (43) Date of publication of application: 04.10.89 Bulletin 89/40
- (45) Publication of the grant of the patent: 09.08.95 Bulletin 95/32
- (84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE
- (56) References cited:
EP-A- 0 236 987
EP-A- 0 251 717
- (73) Proprietor: KYOWA HAKKO KOGYO CO., LTD.
6-1, Ohtemachi 1-chome
Chiyoda-ku,
Tokyo-to (JP)
- (72) Inventor: Yamasaki, Motoo
815, Honmachida
Machida-shi
Tokyo (JP)
Inventor: Yokoo, Yoshiharu
3-4-17, Yokoyama
Sagamihara-shi
Kanagawa (JP)

Inventor: Morimoto, Makoto
1188, Shimotogari
Nagaizumi-cho
Sunto-gun
Shizuoka (JP)
Inventor: Okabe, Masami
410-1, Nameri
Nagaizumi-cho
Sunto-gun
Shizuoka (JP)

- (74) Representative: Kinzebach, Werner, Dr. et al
Patentanwälte
Reitstötter, Kinzebach und Partner
Postfach 86 06 49
D-81633 München (DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

FIELD OF THE INVENTION

5 This invention relates to a chemically modified hG-CSF polypeptide which results from chemical modification of at least one amino group in a polypeptide molecule having human granulocyte colony stimulating factor (hereinafter referred to briefly as hG-CSF) activity and a method of producing such modified polypeptides.

10 BACKGROUND OF THE INVENTION

hG-CSF is a polypeptide which is essential to the proliferation and differentiation of hematopoietic stem cells for the formation of various blood cells and has activity to promote mainly the multiplication of granulocytes, and particularly, of neutrophils. While neutrophils play a vital role in the protection of a living
15 body against infection, they have a short lifetime and must be replenished at all times by the constant multiplication and differentiation of precursor cells. Therapies commonly practiced in recent years for proliferative tumors inhibit the proliferation of precursor cells of neutrophils as well, with the result that they suppress the anti-infective competence of tumor-bearing patients, a serious side effect. hG-CSF promotes the multiplication of neutrophils and, as such, is expected to alleviate this side effect and, at the same time,
20 exert prophylactic and therapeutic effects against infections. Furthermore, hG-CSF has the ability to induce differentiation of cultured leukemia cells *in vitro* and, hence, has the potential for use as a drug for the treatment of leukemia. The chemically modified hG-CSF polypeptide of this invention has hG-CSF activity surpassing that of the known hG-CSF and is expected to be of value as a drug.


As a result of recombinant DNA technology, which has been developing rapidly in recent years, genes
25 for proteinic factors involved in the proliferation and differentiation of blood cells have been isolated one after another. These factors are now produced by various genetic engineering techniques utilizing microbial or animal cells.

Regarding hG-CSF, Nagata et al. isolated cDNA from human squamous cell line CHU-II, determined its DNA sequence and reported on its expression in COS cells [Nagata et al.: *Nature* **319**, 415 (1986)].
30 Moreover, Souza et al. isolated cDNA from human cystic cancer cell line 5637, determined its DNA sequence, and reported on its expression in *Escherichia coli* [Souza et al.: *Science* **232**, 61 (1986)].

It has been reported that in administering the hG-CSF thus obtained to the body, a sustained effect can only be assured by repeated administration of hG-CSF and that discontinuation results in a rapid disappearance of the desired effect [Journal of Experimental Medicine **165**, 941-948 (1987)]. This is
35 probably due to the short life of hG-CSF in the blood.

In regard to enzymes such as asparaginase [Inada, Y. et. al.: *Trends in Biotechnology* **4**, 68-73 (1986)], arginase [Savoca, K.V. et al.: *Biochimica et Biophysica Acta* **578**, 47-53 (1979)], batroxobin [Nishimura, H. et al.: *Life Science* **33**, 1467-1473 (1983)], etc., it has been found that chemical modification with polyethylene glycol results in an increased residence time in blood and in attenuated antigenicity.

40 In EP-A-0 251 717 chemically modified islet-activating protein (IAP) is disclosed. The modified product is obtained by reacting IAP with a triazine compound of the formula



50 wherein R is a hydroxyl protective group, I is an integer of 7 to 700, p is 1 or 2, and X is halogen.

Protein is generally used as a drug in a lyophilized form. There is a problem that, during and/or after lyophilization, protein undergoes physiologocal or chemical changes, e.g., association, polymerization and oxidation due to external factors such as temperature, moisture, oxygen and ultraviolet light. Such changes often result in degradation of the activity of the protein. To overcome the above problem, stabilizers for protein during lyophilization have been investigated. For example, the stabilizers for hG-CSF are described in GB-A-2193631 and JP-A-63-146829 (the term "JP-A" as used herein means "an unexamined published Japanese patent application"). However, it has been required that the protein is further stabilized during and/or lyophilization for the clinical use.

In using hG-CSF as a drug, it is desirable that hG-CSF be stable and remain in the blood long after administration and its antigenicity be attenuated as well as stable during and/or after lyophilization for the practical use. However, there has not been an hG-CSF having such properties and, for that matter, a method for producing it.


SUMMARY OF THE INVENTION

An object of the present invention is to provide a polypeptide having hG-CSF activity, which shows excellent stability and a long life in the blood.


The inventor of this invention has found that when at least one amino group in a polypeptide having hG-CSF activity is chemically modified, the resulting polypeptide stays longer in blood and stable during and/or after lyophilization than the unmodified polypeptide.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a modified polypeptide having hG-CSF activity which is available on substitution of at least one amino group of a polypeptide having hG-CSF activity with a group of the formula



wherein R_1 is an alkyl or alkanoyl group; n is an optionally variable positive integer; X is O, NH or S; R_2 is



[where R_3 is OH, Cl, $O-(CH_2CH_2O)_n-R_1$ (where R_1 and n are as defined above), Y may not be present or represents $Z-(CH_2)_pCO$, (where Z is O, S or NH and p is an optionally variable positive integer)], or $(CO)_m-(CH_2)_tCO$ (where m is 0 or 1; t is an optionally variable positive integer).

The starting polypeptide having hG-CSF activity may be any polypeptide having hG-CSF activity such as a polypeptide having the amino acid sequence shown in Table 1a, a polypeptide available upon replacement of at least one amino acid residue of the amino acid sequence shown in Table 1a with another kind of amino acid, e.g. the hG-CSF derivatives shown in Table 1b, or a polypeptide deficient in 1 to 11 amino acid residues at the N-terminus of the amino acid sequence shown in Table 1a. Aside from the above polypeptides, the hG-CSF derivatives described in EP-A-243153, EP-A-237545 and WO-A-8701132 can also be employed.

Table 1a

5	x	Thr	Pro	Leu	Gly	Pro	Ala	Ser	Ser	Leu	Pro	Gln	Ser	Phe	Leu	Leu	Lys	Cys	Leu	Glu
		1									10									
10		Gln	Val	Arg	Lys	Ile	Gln	Gly	Asp	Gly	Ala	Ala	Leu	Gln	Glu	Lys	Leu	Cys	Ala	Thr
		20									30									
15		Tyr	Lys	Leu	Cys	His	Pro	Glu	Glu	Leu	Val	Leu	Leu	Gly	His	Ser	Leu	Gly	Ile	Pro
		40										50								
20		Trp	Ala	Pro	Leu	Ser	Ser	Cys	Pro	Ser	Gln	Ala	Leu	Gln	Leu	Ala	Gly	Cys	Leu	Ser
		60										70								
25		Gln	Leu	His	Ser	Gly	Leu	Phe	Leu	Tyr	Gln	Gly	Leu	Leu	Gln	Ala	Leu	Glu	Gly	Ile
		80										90								
30		Ser	Pro	Glu	Leu	Gly	Pro	Thr	Leu	Asp	Thr	Leu	Gln	Leu	Asp	Val	Ala	Asp	Phe	Ala
		100										110								
35		Thr	Thr	Ile	Trp	Gln	Gln	Met	Glu	Glu	Leu	Gly	Met	Ala	Pro	Ala	Leu	Gln	Pro	Thr
		120										130								
40		Gln	Gly	Ala	Met	Pro	Ala	Phe	Ala	Ser	Ala	Phe	Gln	Arg	Arg	Ala	Gly	Gly	Val	Leu
		140										150								
45		Val	Ala	Ser	His	Leu	Gln	Ser	Phe	Leu	Glu	Val	Ser	Tyr	Arg	Val	Leu	Arg	His	Leu
		160										170								
50		Ala	Gln	Pro																
		174																		
55		(X = H or Met)																		

1 2 3 4 5 6
 T P L G P A S S L - WT
 A P T Y R A S S L - Claim

Table 1b

Claimed Variant


Position of substitution (an amino acid of hG-CSF)	hG-CSF derivatives										
	a)	b)	c)	d)	e)	f)	g)	h)	i)	j)	k)
Position-1 (Thr)	*	Val	Cys	Tyr	Arg	*	Asn	Ile	Ser	*	Ala
Position-3 (Leu)	Glu	Ile	Ile	Ile	Thr	Thr	Glu	Thr	Thr	*	Thr
Position-4 (Gly)	Lys	Arg	Arg	Arg	Arg	Arg	Arg	Arg	Arg	Arg	Tyr
Position-5 (Pro)	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	*	Arg
Position-17 (Cys)	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser
* No substitution											

Referring to the chemically modifying group to be used in accordance with this invention, the alkyl and alkanoyl groups mentioned as protective groups for the terminal oxygen atom are C₁₋₁₈ alkyl groups (for example, methyl, ethyl, propyl, etc.) and C₁₋₁₈ alkanoyl groups (for example, formyl, acetyl, propionyl, etc.).


The positive integer n is not more than 500 and preferably 7 to 230.

The positive integer l is not more than 100 and preferably 0 to 6. The positive integer p is from 1 to 18, preferably 1 to 6. The molecular weight of said chemically modifying group is not more than 30,000 and preferably in the range of 300 to 20,000.


The chemically modified hG-CSF of this invention is produced, for example, by condensation of hG-CSF with a halide of formula (II)



wherein R₁, n, X and R₃ are as defined hereinbefore or by condensation of hG-CSF with a carboxylic acid of formula (III)




wherein R₁, n, X, m and l are as defined hereinbefore or a carboxylic acid of formula (IV)




wherein R₁, n, Z, X, R₃ and p are as defined hereinbefore.

The halide of formula (II) can be prepared by condensing



(wherein R₁, n and X are as defined above) with cyanuric chloride [Matsushima, A. et al: Chemistry Letters, 773-776, 1980; Abuchowski, A. et al.: Journal of Biological Chemistry 252 (12) 3578-3581, 1977]. This halide is reactive and can therefore be directly reacted with a polypeptide having hG-CSF activity.

The carboxylic acid of formula (III) can be prepared by subjecting



5 This carboxylic acid is not reactive and must, therefore, be activated before use. This activation of the carboxylic acid can for example be accomplished by converting it to an active ester with, for example, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxybenzotriazole, p-nitrophenol or the like, a mixed acid anhydride with isobutyl chloroformate, ethyl chloroformate or the like, or to an acid halide using a halogenating agent such as thionyl chloride. [All of the above methods are described, for example, in
10 Peptide Gosei (Peptide Synthesis) (Nobuo Izumiya et al., Maruzen)].

The chemically modified hG-CSF of this invention is preferably produced by condensing hG-CSF with
15 the carboxylic acid represented by formula (V)



To this polypeptide having hG-CSF activity is added the above-mentioned halide or active carboxylic acid compound in a proportion (mole ratio) of 2 to 100 times the amount of amino groups present in the polypeptide molecule and the mixture is allowed to react at a temperature of 4 to 37 °C, preferably 4 to 10 °C, and pH 7 to 10 for 1 hour to 2 days, preferably 1 to 24 hours, whereby the desired chemically modified hG-CSF is produced.

The degree of chemical modification can be ascertained by quantitating the amount of decrease in free amino groups with trinitrobenzenesulfonic acid or monitoring a change in mobility of chemically modified hG-CSF by sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis.

The conditions at lyophilization are not particularly restricted. The lyophilization is generally carried out by freezing at -50°C or less for 1 to 5 hours, drying at -20°C to 0°C at a vacuum degree of 50 to 150 mTorr for 24 to 48 hours, and further drying at 10 to 30°C at a vacuum degree of 50 to 100 mTorr for 16 to 24 hours.

According to the modified hG-CSF of the invention, 1 to 3 molecules of a polyethylene glycol (PEG) derivative are bound to each molecule (hereinafter referred to as mono-, di- and tri-type hG-CSF, respectively). The above-described modified hG-CSF preparation may be a mixture of the mono-, di- and tri-type hG-CSF or these types of modified hG-CSF may be used as separated each other.

6

Test method 1

The method of Lowry (Lowry, O. H. et al.: Journal of Biological Chemistry 193, 265, 1951).

5 Test method 2

The method of Laemmli (Laemmli, U.K.: Nature 227, 680, 1970) in which SDS-polyacrylamide gel electrophoresis is followed by determination with a chromatoscanner (CS-930, Shimadzu).

The determination of G-CSF activity in this invention was carried out in the following manner.
 10 Myelocytes were aseptically taken from the femoral bone of male C3H/He mice aged 8 to 12 weeks (purchased from Shizuoka Laboratory Animal Center) and suspended in α -Minimum Essential Medium (Flow Laboratories, hereinafter referred to briefly as α -MEM) containing 10% of fetal bovine serum (FBS). This cell suspension (about 5×10^7 cells), 1.5 ml, was applied to a nylon wool (Nylon Fiber 146-04231, Wako Pure Chemical Industries, Ltd.) column (0.3 g) and incubated in a 5% CO₂ incubator at 37°C for 90 minutes.
 15 Then, α -MEM pre-warmed to 37°C was passed through the column, whereby myelocytes not adsorbed on nylon wool were obtained in the effluent. This cell fraction was washed with α -MEM once and adjusted to a specified concentration.

Then, in accordance with the method of Okabe et al. (Okabe, T. et al.: Cancer Research 44, 4503-4506, 1986), the assay of bone marrow hematopoietic cell colony-forming activity was performed. Thus, to a mixture of 0.2 ml of α -MEM, 0.4 ml of FBS and 0.2 ml of doubling sample dilutions was added 0.2 ml of the myelocytes (2×10^6 cells/ml) prepared by the above procedure. The resulting mixture was further mixed with an equal volume (1.0 ml) of 0.6% agar (Difco, Agar purified No. 0560-01) solution maintained at 42°C and a 0.5 ml portion of the resulting mixture was distributed into a 24-well Multidish (Nunc, No. 143982) (5×10^4 cells/well, $n=3$). The dish was maintained in a 5% CO₂ incubator at 37°C for 7 days and
 25 the number of colonies consisting of 40 or more cells was counted under the microscope (Olympus, X40). After this colony counting, each colony was carefully taken out on a glass slide, fixed with acetone-formalin for 30 seconds and subjected to esterase double-staining by the method of Kubota et al. (Kubota, K. et al.: Experimental hematology 8, 339-344, 1980) for identification.

The potency of each sample was calculated from the counts for doubling dilutions in the colony forming test as follows. The activity value giving 1/2 the maximum colony forming value of G-CSF used as a
 30 standard was defined as 50 units and this value was multiplied by the dilution factor of each sample and, for conversion to activity per unit ml, by 20 to arrive at the potency (units) of the sample. The specific activity (units/mg) was expressed in potency per weight (mg) of protein.

The following examples, reference examples and experimental examples are further illustrative of this
 35 invention, but are not construed to limit the scope of the invention.

EXAMPLE 1

To 3 ml of 0.1 M borate buffer (pH 10) containing 186 μ g/ml of hG-CSF with the amino acid sequence
 40 shown in Table 1a was added 56 mg of the chloro-compound prepared in Reference Example 1 and the reaction was carried out at 4°C for 24 hours with stirring.

The unreacted chloro-compound was removed by ultrafiltration (cutoff molecular weight 30,000) and, then, using YMC-Pack AM-312ODS (Kurita Industries, Ltd.), reversed phase HPLC on a linear gradient of 0 to 70% acetonitrile was carried out. The chemically modified hG-CSF polypeptide was eluted in the fraction
 45 of about 50% acetonitrile (yield 30 μ g, percent yield 5%). It was confirmed by SDS-polyacrylamide gel electrophoresis that this chemically modified hG-CSF polypeptide had one chloro compound residue per molecule. The purity was in excess of 90%.

EXAMPLE 2

50 To 50 ml of 50 mM phosphate buffer (pH 7.2) containing 570 μ g/ml of hG-CSF with the amino acid sequence shown in Table 1a was added 240 mg of the active ester prepared in Reference Example 2 and the reaction was carried out at 4°C for 6 hours with stirring.

After addition of 50 ml of 10 mM Tris-HCl buffer-0.7 M ammonium sulfate (pH 8.0), the reaction
 55 mixture was passed through a column (2.2 cm x 26 cm) of butyl-Toyopearl 650M (Tosoh) equilibrated with 10 mM Tris-HCl-0.35 M ammonium sulfate (pH 8.0) at a flow rate of 100 ml/hr. Then, the column was washed by passing 100 ml of 10 mM Tris-HCl-0.35 M ammonium sulfate (pH 8.0) at a flow rate of 100 ml/hr and, then, elution was carried out on a linear gradient with 200 ml of 10 mM Tris-HCl-0.35 M

ammonium sulfate (pH 8.0) to 200 ml of 10 mM Tris-HCl buffer (pH 8.0) at a flow rate of 100 ml/hr. The object compound was eluted in fractions corresponding to 50 mM through 130 mM of ammonium sulfate. These fractions were collected (130 ml), subjected to ultrafiltration (cutoff molecular weight 10,000; membrane YM10 (Amicon), and concentrated to 7 ml. The concentrate obtained was passed through a column (2.8 cm x 70 cm) of Sephacryl S-200 (Pharmacia) equilibrated with 10 mM phosphate buffer-physiological saline (PBS) (pH 7.2) at a flow rate of 120 ml/hr, followed by passage of PBS at the same flow rate. The tri-type chemically modified hG-CSF polypeptide was eluted in fractions corresponding to 150 ml through 160 ml of PBS (yield 2 mg, percent yield 7%). The di- and mono-type modified hG-CSF polypeptides were subsequently eluted in fractions of 165 ml through 185 ml of PBS (yield 1.5 mg, percent yield 5%) and 190 ml through 210 ml of PBS (yield 4.5 mg, percent yield 16%). It was verified by SDS-polyacrylamide gel electrophoresis that, in the mono-type hG-CSF polypeptide, one molecule of the polyethylene glycol derivative carboxylic acid had been bound to each molecule of hG-CSF, two molecules in the di-type hG-CSF and three molecules in the tri-type hG-CSF. The purity of each polypeptide was not less than 90%.

EXAMPLE 3

To 10 ml of 0.1 M borate buffer (pH 9) containing the hG-CSF derivative (570 µg/ml) obtained in Reference Example 3 was added 54 mg of the active ester obtained in Reference Example 2 and the reaction was conducted at 4 °C for 10 hours with stirring.

The unreacted active ester and its decomposition product were removed with an ultrafiltration membrane YM30 (Amicon) and, then, the internal fluid was substituted with 10 mM Tris-HCl buffer (pH 8) using the same membrane. The residual fluid was passed through a column (1.7 cm x 4.4 cm) of DEAE-Toyopearl 650M (Tosoh) equilibrated with 10 mM Tris-HCl buffer (pH 8.0) at a flow rate of 10 ml/hr. Then, the column was washed by passing 20 ml of 10 mM Tris-HCl buffer (pH 8) at a flow rate of 5 ml/hr and, then, elution was carried out on a linear gradient with 50 ml of 10 mM Tris-HCl buffer (pH 8) to 10 mM Tris-HCl-0.4 M NaCl (pH 8) at a flow rate of 5 ml/hr. The chemically modified hG-CSF polypeptide was eluted in fractions corresponding to 100 through 120 mM of NaCl (yield 0.85 mg; percent yield 15%). It was verified by SDS-polyacrylamide gel electrophoresis that, in the resulting polypeptide, one molecule of the polyethylene glycol derivative carboxylic acid had been bound to one molecule of the hG-CSF derivative. The purity of this polypeptide was not less than 90%.

EXAMPLE 4

To 50 ml of 50 mM phosphate buffer (pH 7.2) containing 570 µg/ml of the hG-CSF derivative obtained in Reference Example 3 was added 300 mg of the active ester prepared in Reference Example 2 and the reaction was carried out at 4 °C for 6 hours with stirring.

After addition of 50 ml of 10 mM Tris-HCl buffer-0.7 M ammonium sulfate (pH 8.0), the reaction mixture was passed through a column (2.2 cm x 26 cm) of butyl-Toyopearl 650M (Tosoh) equilibrated with 10 mM Tris-HCl-0.35 M ammonium sulfate (pH 8.0) at a flow rate of 100 ml/hr. Then, the column was washed by passing 100 ml of 10 mM Tris-HCl-0.35 M ammonium sulfate (pH 8.0) at a flow rate of 100 ml/hr and, then, elution was carried out on a linear gradient of 10 mM Tris-HCl buffer (pH 8.0) and 400 ml of 0.35 M to 0 M of ammonium sulfate at a flow rate of 100 ml/hr. The object compound was eluted in fractions corresponding to 50 mM through 150 mM of ammonium sulfate. These fractions were collected (150 ml), subjected to ultrafiltration (cutoff molecular weight 10,000; membrane YM10 (Amicon), and concentrated to 10 ml. The concentrate obtained was passed through a column (2.8 cm x 70 cm) of Sephacryl S-200 (Pharmacia) equilibrated with PBS at a flow rate of 120 ml/hr, followed by passage of PBS at the same flow rate. The tri-type chemically modified hG-CSF polypeptide was eluted in fractions corresponding to 150 ml through 160 ml of PBS (yield 1.5 mg, percent yield 5%). The di- and mono-type modified hG-CSF polypeptides were subsequently eluted in fractions of 165 ml through 185 ml (yield 3 mg, percent yield 11%) and 190 ml through 210 ml (yield 4 mg, percent yield 14%). It was verified by SDS-polyacrylamide gel electrophoresis that, in the mono-type polypeptide, one molecule of the polyethylene glycol derivative carboxylic acid had been bound to each molecule of hG-CSF, two molecules in the di-type polypeptide and three molecules in the tri-type polypeptide. The purity of each polypeptide was not less than 90%.

EXAMPLE 5

To 100 ml of 50 mM phosphate buffer (pH 7.2) containing 300 µg/ml of the hG-CSF derivativ
obtained in Reference Example 3 was added 800 mg of the active ester prepared in Reference Examp
and the reaction was carried out at 4 °C for 24 hours with stirring.

After addition of 100 ml of 10 mM Tris-HCl buffer-0.7 M ammonium sulfate (pH 8.0), the reaction
mixture was passed through a column (2.2 cm x 26 cm) of butyl-Toyopearl 650M (Tosoh) equilibrated with
10 mM Tris-HCl-0.35 M ammonium sulfate (pH 8.0) at a flow rate of 100 ml/hr. Then, the column was
washed by passing 100 ml of 10 mM Tris-HCl-0.35 M ammonium sulfate (pH 8.0) at a flow rate of 100
ml/hr and, then, elution was carried out on a linear gradient of 10 mM Tris-HCl buffer (pH 8.0) and 400 ml
of 0.35 M to 0 M of ammonium sulfate at a flow rate of 100 ml/hr. The object compound was eluted in
fractions corresponding to 0 mM through 250 mM of ammonium sulfate. These fractions were collected
(250 ml), subjected to ultrafiltration (cutoff molecular weight 10,000; membrane YM10 (Amicon), and
concentrated to 10 ml. The concentrate obtained was passed through a column (5.6 cm x 40 cm) of
Sephacryl S-200 (Pharmacia) equilibrated with PBS at a flow rate of 160 ml/hr, followed by passag
of
PBS at the same flow rate. The tri-type chemically modified hG-CSF polypeptide was eluted in fractions
corresponding to 360 ml through 400 ml of PBS (yield 2.1 mg, percent yield 7%). The di- and mono-type
modified hG-CSF polypeptides were subsequently eluted in fractions of 420 ml through 450 ml (yield 1.5
mg, percent yield 5%) and 500 ml through 530 ml (yield 1.5 mg, percent yield 5%). It was verified by
SDS-polyacrylamide gel electrophoresis that, in the mono-type polypeptide, one molecule of the polyethyl-
ene glycol derivative carboxylic acid had been bound to each molecule of hG-CSF, two molecules in the di-
type polypeptide and three molecules in the tri-type polypeptide. The purity of each polypeptide was not
less than 90%.

EXAMPLE 6

Preparation of lyophilization product of chemically modified hG-CSF and storage stability thereof

In the same manner as in Example 2, the hG-CSF was reacted with the active ester prepared in
Reference Example 2. The unreacted active ester and its decomposition product were removed with an
ultrafiltration membrane YM30 (Amicon) and, then, the internal fluid was substituted with 50 mM phosphate
buffer containing 1 M sodium chloride (pH 7.2) using the same membrane. The resulting solution containing
200 µg/ml of the desired modified hG-CSF derivative was subjected to lyophilization.

The lyophilization was carried out by inoculating the hG-CSF solution into glass vials, freezing the vials
at -50 °C or less for 2 hours, drying at -20 °C at a vacuum degree of 100 mTorr for 24 hours and further
drying at 20 °C at a vacuum degree of 80 mTorr for 24 hours. As a control, a mixed solution of the hG-CSF
and polyethylene glycol was lyophilized in the same manner as above. Each lyophilization product was
allowed to stand at 65 °C and sampled at timed intervals. The sampled lyophilization product was dissolved
in 50 mM phosphate buffer

(pH 7.2) to determine the residual G-CSF activity in accordance with the above-described method. The
results are shown in Table 2.

The residual activity means relative activity to the activity before lyophilization and defined as the
following equation.

$$\text{Residual activity (\%)} = \frac{\text{Activity after storage at timed intervals}}{\text{Activity before lyophilization}} \times 100$$

Table 2

Storage stability of lyophilized chemically modified hG-CSF (65 °C)				
Sample	Residual activity (%) at timed intervals			
	6 hrs.	1 day	2 days	7 days
hG-CSF	68	26	2	2
hG-CSF with PEG ¹⁾	53	40	6	<1
hG-CSF with PEG ²⁾	48	33	21	13
Chemically modified hG-CSF	102	57	35	25

Notes

1) 2.5 parts by weight of PEG per part by weight of hG-CSF

2) 5 parts by weight of PEG per part by weight of hG-CSF

EXAMPLE 7

Preparation of lyophilization product of chemically modified hG-CSF and storage stability thereof

In the same manner as in Example 4, the hG-CSF derivative was reacted with the active ester prepared in Reference Example 2, and chemically modified hG-CSF derivative solution was obtained in the same manner as in Example 6. The lyophilization was carried out as described in Example 6 and each lyophilization product was allowed to stand at 37 °C for 7 days. The results are shown in Table 3.

Table 3

Storage stability of chemically modified hG-CSF (37 °C, 7 days)	
Sample	Residual activity (%)
hG-CSF derivative	85
hG-CSF derivative with PEG ¹⁾	94
hG-CSF derivative with PEG ²⁾	88
Chemically modified hG-CSF derivative	100

Notes

1) 2.5 parts by weight of PEG per part by weight of hG-CSF

2) 5 parts by weight of PEG per part by weight of hG-CSF

REFERENCE EXAMPLE 1

Production of 2,4-bis(O-methoxypolyethylene glycol)-6-chloro-s-triazine

In 100 ml of dry toluene containing 10 g of anhydrous sodium carbonate was dissolved 20 g of monomethoxypolyethylene glycol having an average molecular weight of 4000 (Nippon Oil and Fats) and the solution was heated at 110 °C for 30 minutes. Then, 500 mg of cyanuric chloride was added and the mixture was heated at 110 °C for 24 hours. The reaction residue was filtered off, followed by addition of 300 ml of petroleum ether to cause precipitation. The precipitate was washed with several portions of petroleum ether to recover 10 g of 2,4 bis(O-methoxypolyethylene glycol)-6-chloro-s-triazine (yield 50%).

REFERENCE EXAMPLE 2

Synthesis of monomethoxypolyethylene glycol succinyl-N-hydroxysuccinimide ester

- 5 To 50 ml of dry toluene were added 20 g of thoroughly dehydrated monomethoxypolyethylene glycol having an average molecular weight of 5000 (Union Carbide) and 2 g of succinic anhydride and the mixture was refluxed at 150°C for 5 hours. The toluene was distilled off under reduced pressure and the residue was thoroughly solubilized by addition of 30 ml of methylene chloride. To this was added 400 ml of dry ethyl ether to cause precipitation. The precipitate was recrystallized from methylene chloride-ethyl ether
- 10 (volume ratio = 1:3) to recover 10 g (yield about 50%) of succinylated monomethoxypolyethylene glycol. This succinylated product (3.3 g) and 100 mg of N-hydroxysuccinimide were solubilized in 5 ml of dry methylene chloride, followed by addition of 200 mg of dicyclohexylcarbodiimide (DCC) with ice-cooling. The mixture was then stirred at room temperature for 20 hours. The byproduct dicyclohexylurea (DCU) was filtered off and ethyl ether was added to the filtrate to cause precipitation. The resulting precipitate was
- 15 recrystallized from methylene chloride ethyl ether (volume ratio = 1:3) to recover 2.5 g (yield 72%) of monomethoxypolyethylene glycol succinyl-N-hydroxysuccinimide ester.

REFERENCE EXAMPLE 3

- 20 A hG-CSF derivative corresponding to the amino acid sequence shown in Table 1a but containing alanine in lieu of the threonine in position-1, threonine in lieu of the leucine in position-3, tyrosine in lieu of the glycine in position-4, arginine in lieu of the proline in position-5 and serine in lieu of the cysteine in position-17 was prepared by the following procedure.

- Escherichia coli W3110 str A (Escherichia coli ECfBD28, FERM BP-1479) carrying a plasmid pCfBD28
- 25 containing a DNA coding for the above-mentioned hG-CSF derivative was cultured in LG Medium (prepared by dissolving 10 g of Bactotryptone, 5 g of yeast extract, 5 g of NaCl and 1 g of glucose in 1 l of water and adjusting the solution to pH 7.0 with NaOH) at 37°C for 18 hours. A 5-ml portion of this culture was inoculated into 100 ml of MCG Medium (0.6% of Na₂HPO₄, 0.3% of KH₂PO₄, 0.5% of NaCl, 0.5% of casamino acids, 1 mM of MgSO₄ and 4 µg/ml of vitamin B₁; pH 7.2) containing 25 µg/ml of tryptophan
- 30 and 50 µg/ml of ampicillin and incubated at 30°C for 4 to 8 hours. Thereafter, 10 µg/ml of 3β-indoleacrylic acid (hereinafter referred to briefly as IAA), a tryptophan inducer, was added and the incubation was continued for an additional period of 2 to 12 hours. The resulting culture was centrifuged at 8,000 rpm for 10 minutes to harvest the cells which were then washed with 30 mM NaCl-30 mM Tris-HCl buffer (pH 7.5). The washed cells were suspended in 30 ml of the same buffer solution as above and
- 35 subjected to sonic disruption (Branson Sonic Power Company's Sonifier, Cell Disruptor 200, output control 2) (10 minutes). The disrupted cell suspension was centrifuged at 9,000 rpm for 30 minutes to collect the cellular residue. From this cellular residue, the hG-CSF derivative was extracted, purified, solubilized and reconstituted by the method of Marston et al. [F.A.O. Marston et al.: Bio/Technology 2, 800 (1984)].

40 REFERENCE EXAMPLE 4

Production of N-hydroxysuccinimide ester (IVb) of 2,4-bis (o-methoxypolyethylene glycol)-6-(3-carboxypropylamino)-s-triazine (IVa)

- 45 The chloride-compound obtained in Reference Example 1 (500 mg) was dissolved in 9 ml of anhydrous tetrahydrofuran. This solution was added to 1 ml of anhydrous dimethylamide containing 10 mg of γ-amino butyric acid and 28 µl of triethylamine and the resulting mixture was stirred at room temperature for 16 hours. After drying the mixture under reduced pressure, 30 ml of methylene chloride and 15 ml of 10 mM phosphate buffer (pH 10) were added thereto for partition.
- 50 The upper layer was adjusted to pH 1 with 2N HCl and 30 ml of methylene chloride was added thereto for the second partition. The lower layer was fractionated, dried with anhydrous sodium sulfate and subjected to filtration. The filtrate was concentrated under reduced pressure to obtain 150 mg of the carboxylic acid (IVa) (percent yield 30%). The thus-obtained carboxylic acid (IVa) (150 mg) and N-hydroxysuccinimide (3 mg) were solubilized in 1 ml of dry methylene chloride, followed by addition of 6
- 55 mg of DCC with ice-cooling. The mixture was then stirred at room temperature for 12 hours. The byproduct DCU was filtered off and ethyl ether was added to the filtrate to cause precipitation. The thus-formed precipitate was collected by filtration and dried under reduced pressure to obtain 100 mg of the desired ester (IVb) (percent yield 67%).

TEST EXAMPLE 1

Specific activity and mouse leukemia cell NFS60 growth promoting activity of the chemically modified hG-CSF (III)

5

In the same manner as Example 3, the hG-CSF derivative was reacted with the active ester and the unreacted active ester and its decomposition product were removed using an ultrafiltration membrane. Then, using the same membrane as above, the internal fluid was substituted with PBS and the G-CSF activity and NFS60 cell growth promoting activity [Proceedings of the National Academy of Sciences of the USA 82, 6687 (1985)] of the chemically modified hG-CSF derivative in the residual fluid were assayed. The results are shown in Table 4.

Table 4

15

Sample	Specific activity (unit/mg protein)	NFS60 growth promoting activity
hG-CSF derivative	100 %	100 %
Chemically modified hG-CSF derivative	12.9 %	6.9 %

20

It is evident from the above results that the chemically modified hG-CSF derivative retained CSF activity against mouse bone marrow stem cells. It is also clear that the same derivative had a growth promoting effect on NFS60 cells which are known to show G-CSF-dependent growth.

25

TEST EXAMPLE 2

Leukocyte (granulocyte) increasing effect

30

The same chemically modified hG-CSF (III) as used in Test Example 1 was subcutaneously administered to C3H/He mice (male, n=3) either once or once a day for 6 consecutive days. The blood was sampled at timed intervals and the white blood cells (WBC) in peripheral blood were counted. The results are shown in Table 5 (single administration) and Table 6 (repeated administration).

35

Table 5

40

The time course of WBC after single administration (s.c.)								
Sample	Dosage ^{a)} (μ g/mouse)	WBC (% of normal control) Blood sampling interval (hr.)						
		1	5	8	16	24	48	72
hG-CSF derivative	10	75.4	159.1	228.3	166.7	200.1	125.5	110.0
Chemically modified hG-CSF derivative	10	81.1	179.2	259.9	169.8	186.7	177.4 ^{**}	96.5

45

Notes

a) The same weight as hG-CSF protein was administered.

^{**}) P<0.01 (Student's t-test)

50

55

Table 6

The time course of WBC in 6-day repeated administration (s.c.)							
Sample	Dosage ^{a)} (μ g/mouse /day)	WBC (% of normal control) Blood sampling interval (Day)					
		1	2	3	4	5	6
hG-CSF derivative	1	79.3	95.5	85.1	91.2	79.1	116.8
Chemically modified hG-CSF derivative	1	131.1 ^{***}	185.4 ^{***}	148.7 ^{***}	125.9 [*]	124.4 [*]	143.4
hG-CSF derivative	10	163.0	221.5	220.3	289.3	273.0	284.0
Chemically modified hG-CSF derivative	10	120.9	181.3	171.5	273.1	355.4	442.3

Notes

a) The same weight as hG-CSF protein was administered.

*) $P < 0.05$, **) $P < 0.01$, ***) $P < 0.001$ (Student's t-test)

In single administration, increase in WBC peaking at 8 hours after administration were observed but whereas the count declined thereafter to normal in 48 hours after administration in the case of the hG-CSF derivative, a significant increase in WBC was still observed even after 48 hours in the case of the chemically modified hG-CSF derivative.

In repeated administration, particularly in the low dose group, the chemically modified hG-CSF derivative showed a significant leukocyte increasing effect as compared with the hG-CSF derivative.

TEST EXAMPLE 3**Time course of plasma concentration**

The chemically modified hG-CSF derivative as used in Test Example 1 was subcutaneously administered to C3H/He mice (male, $n=3$) either once or once a day for 6 consecutive days. The blood was sampled at timed intervals and the plasma concentration of G-CSF was determined. The results are set forth in Table 7 (single administration) and Table 8 (repeated administration). In some experiments, a single dose of the same chemically modified hG-CSF derivative was intravenously administered (Table 9).

Table 7

Single administration (s.c.)								
Sample	Dosage ^{a)} (μ g/mouse/day)	Plasma concentration (Units/ml ^{b)} plasma, x 10^4) Blood sampling interval						
		15 min	30 min	1 hr	5 hr	7.5 hr	15 hr	24 hr
hG-CSF derivative	10	248.3	772.7	2744.5	214.0	163.3	49.7	6.2
Chemically modified hG-CSF derivative	10	29.8	44.6	208.3	1709.0	1146.7	89.6	21.6

Notes

a) The same weight as G-CSF protein was administered.

b) Calculated from NFS 60 cell growth promoting activity (Half max = 50 U).

Table 8

Repeated administration (s.c.)							
Sample	Dosage ^{a)} (μ g/mouse/day)	Plasma concentration ^{b)} (Units/ml ^{c)} plasma, x 10 ⁴) Blood sampling interval (Day)					
		0	1	2	3	4	5
hG-CSF derivative	10	NT.d) 4.8	1354.9 2.2	692.7 NT.	915.3 -e)	768.8 -	756.4 -
Chemically modified hG-CSF derivative	10	NT. 14.2	92.2 11.3	376.9 NT.	235.9 4.7	53.7 2.2	53.9 2.2

Notes

a) The same weight as G-CSF protein was administered.

b) Upper row: plasma concentration at 1 hr after administration Lower row: plasma concentration at 24 hr after administration

c) calculated from NFS 60 cell growth promoting activity (Half max = 50 U)

d) NT. (not tested)

e) - below detection limit

Table 9

Single administration (i.v.)							
Sample	Dosage ^{a)} (μ g/mouse/day)	Plasma concentration (Units/ml ^{b)} plasma, x 10 ⁴) Blood sampling interval					
		3 min	10 min	30 min	1 hr	2 hr	5 hr
hG-CSF derivative	10	1307	1356	901	631.3	563	355.8
Chemically modified hG-CSF derivative	10	6883	6181	4320	3332	1621	905.6

Notes

a) The same weight as G-CSF protein was administered.

b) calculated from NFS 60 cell growth promoting activity (Half max = 50 U).

In the case of single subcutaneous administration, whereas the plasma concentration of the hG-CSF derivative reached a peak at 1 hour and declined rapidly thereafter, that of the chemically modified hG-CSF derivative showed a gradual increase in 5 to 7 hours after administration and maintained a comparatively high level even after 24 hours (Table 7). On the other hand, in repeated subcutaneous administration, the hG-CSF derivative showed a higher plasma concentration at 1 hour after administration but a lower level at 24 hours and was no longer detected on day 3. In contrast, the chemically modified hG-CSF derivative was detectable even at 24 hours and its concentration was higher than that of the hG-CSF derivative.

In intravenous administration, the chemically modified hG-CSF administration, the chemically modified hG-CSF derivative gave significantly higher plasma concentrations as shown in Table 9.

TEST EXAMPLE 4

Specific activity and mouse leukemia cell NFS60 growth promoting activity of the chemically modified hG-CSF derivative (III)

(1) The chemically modified hG-CSG (III) obtained in Example 2 was assayed in the same manner as in Test Example 1. The results are shown in Table 10.

Table 10

Sample	Specific activity (unit/mg protein)	NFS60 growth promoting activity
Unmodified hG-CSF	100 %	100 %
hG-CSF (III) mono-type	58.0 %	50.8 %
hG-CSF (III) di-type	25.8 %	35.0 %
hG-CSF (III) tri-type	18.2 %	21.0 %

(2) In addition, the chemically modified hG-CSFs (III) and (IV) obtained in Examples 4 and 5, respectively, were assayed as above. The results are shown in Table 11.

Table 11

Sample	Specific activity (unit/mg protein)	NFS60 growth promoting activity
Unmodified hG-CSF	100 %	100 %
hG-CSF (III) mono-type	60.0 %	46.9 %
hG-CSF (III) di-type	28.2 %	24.6 %
hG-CSF (III) tri-type	14.7 %	19.0 %
hG-CSF (IV) mono-type	68.4 %	65.9 %
hG-CSF (IV) di-type	22.2 %	44.6 %
hG-CSF (IV) tri-type	11.9 %	17.6 %

TEST EXAMPLE 5

Leukocyte (granulocyte) increasing effect

(1) The chemically modified hG-CSF (III) obtained in Example 2 was subcutaneously administered to BALB/c mice (male, $n=3$; control group, $n=4$) in an amount of 2.5 μg per animal. The blood was sampled at timed intervals and the WBC in peripheral blood were counted. The results are shown in Table 12.

Table 12

The time course of WBC in single administration (s.c.)					
Sample	WBC (% of normal control) Blood sampling interval (hr.)				
	7	25	32	50	72
Unmodified hG-CSF	150	132	106	107	100
hG-CSF (III) mono-type	161	109	134	86	101
hG-CSF (III) di-type	174	166	176	113	91
hG-CSF (III) tri-type	161	130	152	133	82

(2) In the same manner as above, the chemically modified hG-CSFs (III) and (IV) obtained in Examples 4 and 5, respectively, were assayed. The results are shown in Table 13.

Table 13


5	The time course of WBC in single administration (s.c.)					
	Sample	WBC (% of normal control) Blood sampling interval (hr.)				
		7	25	32	50	72
	Unmodified hG-CSF	143	131	140	104	118
10	hG-CSF (III) mono-type	161	152	143	108	137
	hG-CSF (III) di-type	163	120	200	117	120
	hG-CSF (III) tri-type	184	128	185	131	137
15	hG-CSF (IV) mono-type	153	183	233	124	104
	hG-CSF (IV) di-type	120	156	212	169	110
	hG-CSF (IV) tri-type	122	154	168	217	136

Thus, the chemically modified hG-CSF and chemically modified hG-CSF derivatives of this invention produce an enhanced peripheral leukocyte (granulocyte) increasing effect with improved stability and residence time in the blood and, as such, can be used advantageously in clinical medicines, e.g., a leukocyte growth promoting agent.


Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A modified polypeptide having human granulocyte colony stimulating factor (hG-CSF) activity comprising a polypeptide having hG-CSF activity with at least one amino group thereof substituted with a group of the formula




wherein R_1 is an alkyl or alkanoyl group; n is an optionally variable positive integer; X is O, NH or S; R_2 is




[where R_3 is OH, Cl, $O-(CH_2CH_2O)_n-R_1$, where R_1 and n are as defined above, Y may not be present or represents $Z-(CH_2)_pCO$, where Z is O, S or NH and p is an optionally variable positive integer], or $(CO)_m-(CH_2)_lCO$, where m is 0 or 1; l is an optionally variable positive integer.

2. The modified polypeptide of claim 1, wherein R_1 is a C_{1-18} alkyl or alkanoyl group.
3. The modified polypeptide of claim 1, wherein n is a positive integer of not more than 500.
4. The modified polypeptide of claim 1, wherein l is a positive integer of not more than 100.
5. The modified polypeptide of claim 1, wherein the group of formula (I) has a molecular weight of not more than 30,000.
6. A pharmaceutical composition comprising the modified polypeptide of anyone of claims 1 to 5, optionally in combination with a pharmaceutically acceptable carrier.


7. The pharmaceutical composition of claim 6 containing the modified polypeptid of anyone of claims 1 to 5 in lyophilized form.
8. A process for preparing a chemically modified hG-CSF according to anyone of claims 1 to 5, comprising condensation of hG-CSF with a halide of formula (II)



wherein R_1 , n , X and R_3 are as defined hereinbefore; or condensation of hG-CSF with a carboxylic acid of formula (III)




wherein R_1 , n , X , m and l are as defined hereinbefore; or with a carboxylic acid of formula (IV)



wherein R_1 , n , Z , X , R_3 and p are as defined hereinbefore.

9. The process according to claim 8, comprising condensation of hG-CSF with a carboxylic acid represented by formula (V)




wherein R_1 , n and X are as defined above, Z is O, S or NH and p is an optionally variable positive integer.

10. The process according to claim 8 or 9, characterized in that the halide or active carboxylic acid compound is added to the polypeptide in a proportion (mole ratio) of 2 to 100 times the amount of amino groups present in the polypeptide molecule and the mixture is allowed to react at a temperature of 4 to 37°C, preferably 4 to 10°C, and at pH 7 to 10 for 1 hour to 2 days, preferably 1 to 24 hours, whereby the desired chemically modified hG-CSF is produced.


11. The use of at least one modified polypeptide of claims 1 to 5 for preparing a pharmaceutical composition showing leukocyte growth promoting activity.

Claims for the following Contracting State : ES


1. A process for preparing a modified polypeptide having human granulocyte colony stimulating factor (hG-CSF) activity comprising a polypeptide having hG-CSF activity with at least one amino group thereof substituted with a group of the formula




wherein R_1 is an alkyl or alkanoyl group; n is an optionally variable positive integer; X is O, NH or S; R_2 is




[where R_3 is OH, Cl, $O-(CH_2CH_2O)_n-R_1$, where R_1 and n are as defined above, Y may not be present or represents $Z-(CH_2)_pCO$, where Z is O, S or NH and p is an optionally variable positive integer], or $(CO)_m-(CH_2)_lCO$, where m is 0 or 1; l is an optionally variable positive integer; which process comprises condensation of hG-CSF with a halide of formula (II)



wherein R_1 , n , X and R_3 are as defined hereinbefore; or condensation of hG-CSF with a carboxylic acid of formula (III)




wherein R_1 , n , X , m and l are as defined hereinbefore; or with a carboxylic acid of formula (IV)



wherein R_1 , n , Z , X , R_3 and p are as defined hereinbefore.

2. The process according to claim 1, comprising condensation of hG-CSF with a carboxylic acid represented by formula (V)




10 wherein R_1 , n and X are as defined above, Z is O, S or NH and p is an optionally variable positive integer.


3. The process according to claim 1 or 2, characterized in that the halide or active carboxylic acid compound is added to the polypeptide in a proportion (mole ratio) of 2 to 100 times the amount of amino groups present in the polypeptide molecule and the mixture is allowed to react at a temperature of 4 to 37°C, preferably 4 to 10°C and at pH 7 to 10 for 1 hour to 2 days, preferably 1 to 24 hours, whereby the desired chemically modified hG-CSF is produced.
4. The process of one of the claims 1 to 3, wherein R₁ is a C₁₋₁₈ alkyl or alkanoyl group.
5. The process of one of the claims 1 to 3, wherein n is a positive integer of not more than 500.
6. The process of one of the claims 1 to 3, wherein l is a positive integer of not more than 100.
7. The process of one of the claims 1 to 3, wherein the group of formula (I) has a molecular weight of not more than 30,000.
8. A process for preparing a pharmaceutical composition which process comprises providing a modified polypeptide as defined in anyone of claims 1 to 7, optionally in combination with a pharmaceutically acceptable carrier.
9. The process of claim 8 which process comprises providing the modified polypeptide as defined in anyone of claims 1 to 7 in lyophilized form.

35 **Claims for the following Contracting State : GR**

1. A modified polypeptide having human granulocyte colony stimulating factor (hG-CSF) activity comprising a polypeptide having hG-CSF activity with at least one amino group thereof substituted with a group of the formula




wherein R₁ is an alkyl or alkanoyl group; n is an optionally variable positive integer; X is O, NH or S;
R₂ is




[where R₃ is OH, Cl, O-(CH₂CH₂O)_n-R₁, where R₁ and n are as defined above, Y may not be present or represents Z-(CH₂)_pCO, where Z is O, S or NH and p is an optionally variable positive integer], or (CO)-_m-(CH₂)_lCO, where m is 0 or 1; l is an optionally variable positive integer.


2. The modified polypeptide of claim 1, wherein R_1 is a C_{1-18} alkyl or alkanoyl group.
3. The modified polypeptide of claim 1, wherein n is a positive integer of not more than 500.
- 5 4. The modified polypeptide of claim 1, wherein l is a positive integer of not more than 100.
5. The modified polypeptide of claim 1, wherein the group of formula (I) has a molecular weight of not more than 30,000.
- 10 6. A process for preparing a pharmaceutical composition which process comprises providing a modified polypeptide as defined in anyone of claims 1 to 5, optionally in combination with a pharmaceutically acceptable carrier.
7. The process of claim 6 which process comprises providing the modified polypeptide as defined in
15 anyone of claims 1 to 5 in lyophilized form.
8. A process for preparing a chemically modified hG-CSF according to anyone of claims 1 to 5, comprising condensation of hG-CSF with a halide of formula (II)



wherein R_1 , n , X and R_3 are as defined hereinbefore; or condensation of hG-CSF with a carboxylic acid of formula (III)




wherein R_1 , n , X , m and l are as defined hereinbefore; or with a carboxylic acid of formula (IV)



wherein R_1 , n , Z , X , R_3 and p are as defined hereinbefore.

9. The process according to claim 8, comprising condensation of hG-CSF with a carboxylic acid represented by formula (V)



wherein R_1 , n and X are as defined above, Z is O, S or NH and p is an optionally variable positive


integer.

10. The process according to claim 8 or 9, characterized in that the halide or active carboxylic acid compound is added to the polypeptide in a proportion (mole ratio) of 2 to 100 times the amount of amino groups present in the polypeptide molecule and the mixture is allowed to react at a temperature of 4 to 37 °C, preferably 4 to 10 °C, and at pH 7 to 10 for 1 hour to 2 days, preferably 1 to 24 hours, whereby the desired chemically modified hG-CSF is produced.
11. The use of at least one modified polypeptide of claims 1 to 5 for preparing a pharmaceutical composition showing leukocyte growth promoting activity.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Modifiziertes Polypeptid mit Aktivität von humanem Granulozyten-Kolonie-stimulierenden Faktor (hG-CSF), umfassend ein Polypeptid mit hG-CSF-Aktivität, wobei wenigstens eine Aminosäuregruppe davon mit einer Gruppe der Formel




substituiert ist, worin

R_1 für eine Alkyl- oder Alkanoylgruppe steht;

n für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht;

X für O, NH oder S steht;


R_2 für



steht, [worin R_3 für OH, Cl, $O-(CH_2CH_2O)_n-R_1$ steht, worin R_1 und n die oben angegebenen Bedeutungen besitzen, Y fehlt oder für $Z-(CH_2)_pCO$ steht, worin Z für O, S oder NH steht und p für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht]; oder für $(CO)_m-(CH_2)_lCO$ steht, worin m für 0 oder 1 steht; und l für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht.


2. Modifiziertes Polypeptid nach Anspruch 1, worin R_1 für eine C_{1-18} -Alkyl- oder -Alkanoylgruppe steht.
3. Modifiziertes Polypeptid nach Anspruch 1, worin n für einen positiven, ganzzahligen Wert steht, der nicht größer als 500 ist.
4. Modifiziertes Polypeptid nach Anspruch 1, worin l für einen positiven, ganzzahligen Wert steht, der nicht größer als 100 ist.
5. Modifiziertes Polypeptid nach Anspruch 1, worin die Gruppe der Formel (I) ein Molekulargewicht von nicht mehr als 30000 besitzt.
6. Pharmazeutisches Mittel, umfassend ein modifiziertes Polypeptid gemäß einem der Ansprüche 1 bis 5, gegebenenfalls in Kombination mit einem pharmazeutisch akzeptablen Träger.
7. Pharmazeutisches Mittel nach Anspruch 6, enthaltend das modifizierte Polypeptid gemäß einem der Ansprüche 1 bis 5 in lyophilisierter Form.

8. Verfahren zur Herstellung eines chemisch modifizierten hG-CSF gemäß einem der Ansprüche 1 bis 5, umfassend die Kondensation von hG-CSF mit einem Halogenid der Formel (II)




worin R_1 , n , X und R_3 die oben angegebenen Bedeutungen besitzen;
oder

die Kondensation von hG-CSF mit einer Carbonsäure der Formel (III)




worin R_1 , n , X , m und l die oben angegebenen Bedeutungen besitzen; oder mit einer Carbonsäure der Formel (IV)



worin R_1 , n , Z , X , R_3 und p die oben angegebenen Bedeutungen besitzen.

9. Verfahren nach Anspruch 8, umfassend die Kondensation von hG-CSF mit einer Carbonsäure der Formel (V)




worin R_1 , n und X die oben angegebenen Bedeutungen besitzen, Z für O, S oder NH steht und p für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht.

10. Verfahren nach Anspruch 8 oder 9, dadurch gekennzeichnet, daß man das Halogenid oder die aktive Carbonsäureverbindung zum Polypeptid in einem Anteil (Molverhältnis) entsprechend dem 2- bis 100-fachen der Menge an in dem Polypeptidmolekül vorliegenden Aminogruppen zugibt und das Gemisch bei einer Temperatur von 4 bis 37°C, vorzugsweise 4 bis 10°C, und bei einem pH von 7 bis 10 1 Stunde bis 2 Tage, vorzugsweise 1 bis 24 Stunden, reagieren läßt, wobei der gewünschte chemisch modifizierte hG-CSF produziert wird.

11. Verwendung von wenigstens einem modifizierten Polypeptid nach Anspruch 1 bis 5 zur Herstellung eines pharmazeutischen Mittels mit Leukozytenwachstum-fördernder Aktivität.

Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zur Herstellung eines modifizierten Polypeptids mit Aktivität von humanem Granulozyten-Kolonie-stimulierenden Faktor (hG-CSF), umfassend ein Polypeptid mit hG-CSF-Aktivität, wobei wenigstens eine Aminosäuregruppe davon mit einer Gruppe der Formel




substituiert ist, worin

R_1 für eine Alkyl- oder Alkanoylgruppe steht;


n für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht;

X für O, NH oder S steht;

R_2 für




steht, [worin R_3 für OH, Cl, $O-(CH_2CH_2O)_n-R_1$ steht, worin R_1 und n die oben angegebenen Bedeutungen besitzen, Y fehlt oder für $Z-(CH_2)_pCO$ steht, worin Z für O, S oder NH steht und p für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht]; oder für $(CO)_m-(CH_2)_lCO$ steht, worin m für 0 oder 1 steht; und l für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht; umfassend die Kondensation von hG-CSF mit einem Halogenid der Formel (II)




worin R_1 , n , X und R_3 die oben angegebenen Bedeutungen besitzen;
oder

die Kondensation von hG-CSF mit einer Carbonsäure der Formel (III)




worin R_1 , n , X , m und l die oben angegebenen Bedeutungen besitzen; oder mit einer Carbonsäure der Formel (IV)



worin R_1 , n , Z , X , R_3 und p die oben angegebenen Bedeutungen besitzen.

2. Verfahren nach Anspruch 1, umfassend die Kondensation von hG-CSF mit einer Carbonsäure der Formel (V)




worin R_1 , n und X die oben angegebenen Bedeutungen besitzen, Z für O, S oder NH steht und p für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht.

3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß man das Halogenid oder die aktive Carbonsäureverbindung zum Polypeptid in einem Anteil (Molverhältnis) entsprechend dem 2- bis 100-fachen der Menge an in dem Polypeptidmolekül vorliegenden Aminogruppen zugibt und das Gemisch bei einer Temperatur von 4 bis 37°C, vorzugsweise 4 bis 10°C, und bei einem pH von 7 bis 10 1 Stunde bis 2 Tage, vorzugsweise 1 bis 24 Stunden, reagieren läßt, wobei der gewünschte chemisch modifizierte hG-CSF produziert wird.
4. Verfahren gemäß einem der Ansprüche 1 bis 3, worin R_1 für eine C_{1-18} -Alkyl- oder -Alkanoylgruppe steht.
5. Verfahren gemäß einem der Ansprüche 1 bis 3, worin n für einen positiven, ganzzahligen Wert steht, der nicht größer als 500 ist.
6. Verfahren gemäß einem der Ansprüche 1 bis 3, worin l für einen positiven, ganzzahligen Wert steht, der nicht größer als 100 ist.
7. Verfahren gemäß einem der Ansprüche 1 bis 3, worin die Gruppe der Formel (I) ein Molekulargewicht von nicht mehr als 30000 besitzt.
8. Verfahren zur Herstellung eines pharmazeutisches Mittels, wobei man bei diesem Verfahren ein modifiziertes Polypeptid gemäß einem der Ansprüche 1 bis 7, gegebenenfalls in Kombination mit einem pharmazeutisch akzeptablen Träger bereitstellt.
9. Verfahren nach Anspruch 8, wobei man bei diesem Verfahren ein modifiziertes Polypeptid gemäß einem der Ansprüche 1 bis 7 in lyophilisierter Form bereitstellt.

Patentansprüche für folgenden Vertragsstaat : GR

1. Modifiziertes Polypeptid mit Aktivität von humanem Granulozyten-Kolonie-stimulierenden Faktor (hG-CSF), umfassend ein Polypeptid mit hG-CSF-Aktivität, wobei wenigstens eine Aminosäuregruppe davon mit einer Gruppe der Formel




substituiert ist, worin

R_1 für eine Alkyl- oder Alkanoylgruppe steht;


n für einen gegebenenfalls variablen, positiven ganzzahligen Wert steht;

X für O, NH oder S steht;


R_2 für




- steht, [worin R_3 für OH, Cl, $\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{R}_1$ steht, worin R_1 und n die oben angegebenen Bedeutungen besitzen, Y fehlt oder für $\text{Z}-(\text{CH}_2)_p\text{CO}$ steht, worin Z für O, S oder NH steht und p für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht]; oder für $(\text{CO})_m-(\text{CH}_2)_1\text{CO}$ steht, worin m für 0 oder 1 steht; und l für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht.
2. Modifiziertes Polypeptid nach Anspruch 1, worin R_1 für eine C_{1-18} -Alkyl- oder -Alkanoylgruppe steht.
 3. Modifiziertes Polypeptid nach Anspruch 1, worin n für einen positiven, ganzzahligen Wert steht, der nicht größer als 500 ist.
 4. Modifiziertes Polypeptid nach Anspruch 1, worin l für einen positiven, ganzzahligen Wert steht, der nicht größer als 100 ist.
 5. Modifiziertes Polypeptid nach Anspruch 1, worin die Gruppe der Formel (I) ein Molekulargewicht von nicht mehr als 30000 besitzt.
 6. Verfahren zur Herstellung eines pharmazeutisches Mittels, wobei man bei diesem Verfahren ein modifiziertes Polypeptid gemäß einem der Ansprüche 1 bis 5, gegebenenfalls in Kombination mit einem pharmazeutisch akzeptablen Träger bereitstellt.
 7. Verfahren nach Anspruch 6, wobei man bei diesem Verfahren ein modifiziertes Polypeptid gemäß einem der Ansprüche 1 bis 5 in lyophilisierter Form bereitstellt.
 8. Verfahren zur Herstellung eines chemisch modifizierten hG-CSF gemäß einem der Ansprüche 1 bis 5, umfassend die Kondensation von hG-CSF mit einem Halogenid der Formel (II)



worin R_1 , n , X und R_3 die oben angegebenen Bedeutungen besitzen;
oder
die Kondensation von hG-CSF mit einer Carbonsäure der Formel (III)




worin R_1 , n , X, m und l die oben angegebenen Bedeutungen besitzen; oder mit einer Carbonsäure der Formel (IV)



10 worin R_1 , n , Z , X , R_3 und p die oben angegebenen Bedeutungen besitzen.

9. Verfahren nach Anspruch 8, umfassend die Kondensation von hG-CSF mit einer Carbonsäure der Formel (V)



25 worin R_1 , n und X die oben angegebenen Bedeutungen besitzen, Z für O, S oder NH steht und p für einen gegebenenfalls variablen, positiven, ganzzahligen Wert steht.


10. Verfahren nach Anspruch 8 oder 9, dadurch gekennzeichnet, daß man das Halogenid oder die aktive Carbonsäureverbindung zum Polypeptid in einem Anteil (Molverhältnis) entsprechend dem 2- bis 100-fachen der Menge an in dem Polypeptidmolekül vorliegenden Aminogruppen zugibt und das Gemisch bei einer Temperatur von 4 bis 37°C, vorzugsweise 4 bis 10°C, und bei einem pH von 7 bis 10 1 Stunde bis 2 Tage, vorzugsweise 1 bis 24 Stunden, reagieren läßt, wobei der gewünschte chemisch modifizierte hG-CSF produziert wird.

11. Verwendung von wenigstens einem modifizierten Polypeptid nach Anspruch 1 bis 5 zur Herstellung eines pharmazeutischen Mittels mit Leukozytenwachstum-fördernder Aktivität.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE


- 40 1. Polypeptide modifié ayant une activité de facteur de stimulation des colonies de granulocytes humain (hG-CSF), comprenant un polypeptide ayant une activité de hG-CSF, dont au moins un groupe amino est substitué par un groupe de formule



45

dans laquelle R_1 est un groupe alkyle ou alcanoyle; n est un entier positif éventuellement variable; X est O, NH ou S; R_2 est

50




55


[où R_3 est OH, Cl, $\text{O}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{R}_1$, R_1 et n ayant la définition donnée ci-dessus, Y peut ne pas être présent ou représente $\text{Z}-(\text{CH}_2)_p\text{CO}$, où Z est O, S ou NH et p est un entier positif éventuellement

variabl], ou $(CO)_m-(CH_2)_1CO$, où m est 0 ou 1; l est un entier positif éventuellement variable.


2. Polypeptide modifié selon la revendication 1, dans lequ l R_1 est un groupe alkyle ou alcanoyl en C_1-C_{18} .
3. Polypeptide modifié selon la revendication 1, dans lequel n est un entier positif inférieur ou égal à 500.
4. Polypeptide modifié selon la revendication 1, dans lequel l est un entier positif inférieur ou égal à 100.
5. Polypeptide modifié selon la revendication 1, dans lequel le groupe de formule (I) a une mass moléculaire inférieure ou égale à 30 000.
6. Composition pharmaceutique comprenant un polypeptide modifié selon l'une quelconque des revendications 1 à 5, éventuellement en combinaison avec un support pharmaceutiquement acceptable.
7. Composition pharmaceutique selon la revendication 6, contenant le polypeptide modifié selon l'une quelconque des revendications 1 à 5 sous forme lyophilisée.
8. Procédé de préparation d'un hG-CSF chimiquement modifié selon l'une quelconque des revendications 1 à 5, comprenant la condensation de hG-CSF avec un halogénure de formule (II)



dans laquelle R_1 , n, X et R_3 sont tels que définis précédemment; ou la condensation de hG-CSF avec un acide carboxylique de formule (III)




dans laquelle R_1 , n, X, m et l sont tels que définis précédemment; ou avec un acide carboxylique de formule (IV)



dans laquelle R_1 , n, Z, X, R_3 et p sont tels que définis précédemment.

9. Procédé selon la revendication 8, comprenant la condensation de hG-CSF avec un acide carboxylique représenté par la formule (V)




10 dans laquelle R_1 , n et X sont tels que définis ci-dessus: Z est O, S ou NH et p est un entier positif éventuellement variable.

15 10. Procédé selon la revendication 8 ou 9, caractérisé en ce que l'on ajoute l'halogénure ou l'acide carboxylique actif au polypeptide en une proportion (rapport molaire) de 2 à 100 fois la quantité de groupes amino présents dans la molécule du polypeptide, et en ce qu'on laisse le mélange réagir à une température de 4 à 37 °C, de préférence de 4 à 10 °C, et à un pH de 7 à 10 pendant 1 heure à 2 jours, de préférence pendant 1 à 24 heures, grâce à quoi on produit le hG-CSF chimiquement modifié désiré.


20 11. Utilisation d'au moins un polypeptide modifié selon les revendications 1 à 5 pour la préparation d'une composition pharmaceutique manifestant une activité de promotion de la croissance des leucocytes.

Revendications pour l'Etat contractant suivant : ES

25 1. Procédé de préparation d'un polypeptide modifié ayant une activité de facteur de stimulation des colonies de granulocytes humain (hG-CSF), comprenant un polypeptide ayant une activité de hG-CSF, dont au moins un groupe amino est substitué par un groupe de formule




dans laquelle R₁ est un groupe alkyle ou alcanoyle; n est un entier positif éventuellement variable; X est O, NH ou S; R₂ est




[où R_3 est OH, Cl, $O-(CH_2CH_2O)_n-R_1$, R_1 et n ayant la définition donnée ci-dessus, Y peut ne pas être présent ou représente $Z-(CH_2)_pCO$, où Z est O, S ou NH et p est un entier positif éventuellement variable], ou $(CO)_m-(CH_2)_1CO$, où m est 0 ou 1; l est un entier positif éventuellement variable;


le procédé comprenant la condensation de hG-CSF avec un halogénure de formule (II)



55 dans laquelle R_1 , n , X et R_3 sont tels que définis précédemment; ou la condensation de hG-CSF avec un acide carboxylique de formule (III)




dans laquelle R_1 , n , X , m et l sont tels que définis précédemment; ou avec un acide carboxylique de formule (IV)



dans laquelle R_1 , n , Z , X , R_3 et p sont tels que définis précédemment.

2. Procédé selon la revendication 1, comprenant la condensation de hG-CSF avec un acide carboxylique représenté par la formule (V)




dans laquelle R_1 , n et X sont tels que définis ci-dessus: Z est O, S ou NH et p est un entier positif éventuellement variable.


3. Procédé selon la revendication 1 ou 2, caractérisé en ce que l'on ajoute l'halogénure ou l'acide carboxylique actif au polypeptide en une proportion (rapport molaire) de 2 à 100 fois la quantité de groupes amino présents dans la molécule du polypeptide, et en ce qu'on laisse le mélange réagir à une température de 4 à 37°C, de préférence de 4 à 10°C, et à un pH de 7 à 10 pendant 1 heure à 2 jours, de préférence pendant 1 à 24 heures: grâce à quoi on produit le hG-CSF chimiquement modifié désiré.
4. Procédé selon l'une des revendications 1 à 3, dans lequel R_1 est un groupe alkyle ou alcanoyle en C_1 - C_{18} .
5. Procédé selon l'une des revendications 1 à 3, dans lequel n est un entier positif inférieur ou égal à 500.
6. Procédé selon l'une des revendications 1 à 3, dans lequel l est un entier positif inférieur ou égal à 100.
7. Procédé selon l'une des revendications 1 à 3, dans lequel le groupe de formule (I) a une masse moléculaire inférieure ou égale à 30 000.
8. Procédé de préparation d'une composition pharmaceutique, ce procédé comprenant la fourniture d'un polypeptide modifié tel que défini dans l'une quelconque des revendications 1 à 7, éventuellement en combinaison avec un support pharmaceutiquement acceptable.
9. Procédé selon la revendication 8, ce procédé comprenant la fourniture du polypeptide modifié tel que défini dans l'une quelconque des revendications 1 à 7 sous forme lyophilisée.

Revendications pour l'Etat contractant suivant : GR

1. Polypeptide modifié ayant une activité de facteur de stimulation des colonies de granulocytes humain (hG-CSF), comprenant un polypeptide ayant une activité de hG-CSF, dont au moins un group amino est substitué par un groupe de formule




dans laquelle R_1 est un groupe alkyle ou alcanoyle; n est un entier positif éventuellement variable; X est O, NH ou S; R_2 est




[où R_3 est OH, Cl, $O-(CH_2CH_2O)_n-R_1$, R_1 et n ayant la définition donnée ci-dessus, Y peut ne pas être présent ou représente $Z-(CH_2)_pCO$ où Z est O, S ou NH et p est un entier positif éventuellement variable], ou $(CO)_m-(CH_2)_lCO$, où m est 0 ou 1; l est un entier positif éventuellement variable.


2. Polypeptide modifié selon la revendication 1, dans lequel R_1 est un groupe alkyle ou alcanoyle en C_1 - C_{18} .
3. Polypeptide modifié selon la revendication 1, dans lequel n est un entier positif inférieur ou égal à 500.
4. Polypeptide modifié selon la revendication 1, dans lequel l est un entier positif inférieur ou égal à 100.
5. Polypeptide modifié selon la revendication 1, dans lequel le groupe de formule (I) a une masse moléculaire inférieure ou égale à 30 000.
6. Procédé de préparation d'une composition pharmaceutique, le procédé comprenant la fourniture d'un polypeptide modifié tel que défini dans l'une quelconque des revendications 1 à 5, éventuellement en combinaison avec un support pharmaceutiquement acceptable.
7. Procédé selon la revendication 6, ce procédé comprenant la fourniture du polypeptide modifié tel que défini dans l'une quelconque des revendications 1 à 5 sous forme lyophilisée.
8. Procédé de préparation d'un hG-CSF chimiquement modifié selon l'une quelconque des revendications 1 à 5, comprenant la condensation de hG-CSF avec un halogénure de formule (II)



dans laquelle R_1 , n , X et R_3 sont tels que définis précédemment; ou la condensation de hG-CSF avec un acide carboxylique de formule (III)




dans laquelle R_1 , n , X , m et l sont tels que définis précédemment; ou avec un acide carboxylique de formule (IV)



dans laquelle R_1 , n , Z , X , R_3 et p sont tels que définis précédemment.

9. Procédé selon la revendication 8, comprenant la condensation de hG-CSF avec un acide carboxylique représenté par la formule (V)



dans laquelle R_1 , n et X sont tels que définis ci-dessus, Z est O, S ou NH et p est un entier positif éventuellement variable.

10. Procédé selon la revendication 8 ou 9, caractérisé en ce que l'on ajoute l'halogénure ou l'acide carboxylique actif au polypeptide en une proportion (rapport molaire) de 2 à 100 fois la quantité de groupes amino présents dans la molécule du polypeptide, et en ce qu'on laisse le mélange réagir à une température de 4 à 37°C, de préférence de 4 à 10°C et à un pH de 7 à 10 pendant 1 heure à 2 jours, de préférence pendant 1 à 24 heures, grâce à quoi on produit le hG-CSF chimiquement modifié désiré.

11. Utilisation d'au moins un polypeptide modifié selon les revendications 1 à 5 pour la préparation d'une composition pharmaceutique manifestant une activité de promotion de la croissance des leucocytes.